Chris J van Koppen

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Induced Pluripotent Stem Cells

Bone Mineral Density

Reactive Oxygen Species

Top Venues

Journal of medicinal chemistry

ACS medicinal chemistry letters

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed Salah, Mariam Tahoun, Jeannette Rudzitis-Auth, Lisa Stotz, Chris J van Koppen, Matthias W Laschke, Ahmed S Abdelsamie, Martin Frotscher
Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model. Journal of medicinal chemistry (2023)
Emanuele M Gargano, Abdelrahman Mohamed, Ahmed S Abdelsamie, Giuseppe Felice Mangiatordi, Hanna Drzewiecka, Paweł P Jagodziński, Arcangela Mazzini, Chris J van Koppen, Matthias W Laschke, Nicolotti Orazio, Angelo Carotti, Sandrine Marchais-Oberwinkler, Rolf Wolfgang Hartmann, Martin Frotscher
17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer. ACS medicinal chemistry letters 12 (12) (2021)
Ahmed S Abdelsamie, Mohamed Salah, Lorenz Siebenbürger, Ahmed Merabet, Claudia Scheuer, Martin Frotscher, Sebastian T Müller, Oliver Zierau, Günter Vollmer, Michael D Menger, Matthias W Laschke, Chris J van Koppen, Sandrine Marchais-Oberwinkler, Rolf Wolfgang Hartmann
Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis. Journal of medicinal chemistry 62 (15) (2019)
Ahmed S Abdelsamie, Steven Herath, Yannik Biskupek, Carsten Börger, Lorenz Siebenbürger, Mohamed Salah, Claudia Scheuer, Sandrine Marchais-Oberwinkler, Martin Frotscher, Tim Pohlemann, Michael D Menger, Rolf Wolfgang Hartmann, Matthias W Laschke, Chris J van Koppen
Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing. Journal of medicinal chemistry 62 (3) (2019)
Lorenz Siebenbuerger, Victor Hernandez-Olmos, Ahmed S Abdelsamie, Martin Frotscher, Chris J van Koppen, Sandrine Marchais-Oberwinkler, Claudia Scheuer, Matthias W Laschke, Michael D Menger, Carsten Boerger, Rolf Wolfgang Hartmann
Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy. Journal of medicinal chemistry 61 (23) (2018)